Sunday, October 26, 2025 10/26/2025

Nuclear pore complex quality control in ALS/FTD

Award Number: R01NS122236
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2021
PERIOD OF PERFORMANCE END DATE: 04/30/2026

Group Awards By:

View Award Description

Nuclear pore complex quality control in ALS/FTD - PROJECT SUMMARY/ABSTRACT Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), the second most common form of dementia, comprise a spectrum of fatal neurodegenerative diseases. An intronic GGGGCC (G4C2) hexanucleotide repeat expansion (HRE) in the C9orf72 gene, have been linked to ALS and FTD, although clinically two distinct diseases. The C9orf72 HRE is the most common cause of both familial and sporadic ALS accounting for ~40% and ~8% of patients respectively. Overall, about 10% of ALS cases are familial with the remaining 90% being sporadic. The molecular mechanisms underlying disease pathogenesis remain poorly understood. Defects in nucleocytoplasmic transport (NCT) and the nuclear pore complex (NPC) have recently emerged as a prominent pathomechanism underlying multiple neurodegenerative diseases including C9orf72 ALS/FTD, subsets of sporadic ALS, Alzheimer’s Disease, and Huntington’s Disease. However, little is known about the nature of the injury to the NPC and its individual nucleoporin components themselves. Using induced pluripotent stem cell derived spinal neurons (iPSNs) and postmortem human tissue, we have amassed data that loss of the transmembrane nucleoporin POM121 from NPCs initiates a pathological cascade impacting NPC composition, function and downstream cellular survival. Notably, loss of POM121 is mediated by pathologic G4C2 repeat RNA and not dipeptide repeat poly peptides or loss of C9ORF72 protein. Given that POM121 protein is not mislocalized and POM121 RNA metabolism is unaltered, we hypothesized that POM121 and subsequently altered nucleoporin proteins are aberrantly degraded in the early stages of C9orf72 ALS/FTD pathogenesis. Recent work in yeast and non-neuronal mammalian cells has shown that nuclear CHMP7 “activates” ESCRT-III mediated degradation of nuclear pore complexes and nuclear envelope components during nuclear pore surveillance and homeostasis. Our new preliminary data suggests that the loss of POM121 from the nucleoplasm and NPCs is initiated by nuclear accumulation of CHMP7. Mechanistically, increased nuclear CHMP7 appears to be the result of G4C2 repeat RNA mediated impaired nuclear export. Thus, our data strongly implicate a CHMP7 degradative pathway in disease pathogenesis. Intriguingly, knockdown of CHMP7 mitigates NPC injury in C9orf72 iPSNs making CHMP7 an attractive therapeutic target in neurodegeneration. In this proposal we will comprehensively investigate this new pathway including studies to 1) Determine the degradative pathway by which CHMP7 mediates nucleoporin removal from NPCs in iPSNs, 2) Investigate the mechanism by which pathologic G4C2 repeat RNA initiates CHMP7 mediated NPC injury. And finally, 3) using a large battery of individual patient iPSN spinal neuron cell lines, evaluate the ability of CHMP7 antisense oligonucleotides to mitigate C9orf72 ALS/FTD and sporadic ALS mediated alterations in the nuclear pore complex and nucleocytoplasmic transport and downstream sensitivity to stressors in iPSNs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $772,375 )
2025	2025	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	7/24/2025	NON-COMPETING CONTINUATION	$772,375
														Subtotal = $772,375

Issue Date FY: 2024 ( Subtotal = $836,025 )
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	5/22/2024	NON-COMPETING CONTINUATION	$772,375
2024	2024	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	4	8/12/2024	SUPPLEMENT FOR EXPANSION	$63,650
														Subtotal = $836,025

Issue Date FY: 2023 ( Subtotal = $791,916 )
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	5/18/2023	NON-COMPETING CONTINUATION	$772,375
2023	2023	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	9/7/2023	SUPPLEMENT FOR EXPANSION	$19,541
														Subtotal = $791,916

Issue Date FY: 2022 ( Subtotal = $816,483 )
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	4/29/2022	NON-COMPETING CONTINUATION	$772,375
2022	2022	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	9/17/2022	SUPPLEMENT FOR EXPANSION	$44,108
														Subtotal = $816,483

Issue Date FY: 2021 ( Subtotal = $788,313 )
2021	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	4/15/2021	NEW	$788,313
														Subtotal = $788,313

Grand Total All Awards = $4,005,112

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nuclear pore complex quality control in ALS/FTD

Award Number: R01NS122236

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2021

PERIOD OF PERFORMANCE END DATE: 04/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer